Wang et al. performed an IHC analysis in 87 NSCLC patients and 30 SCLC patients, reporting PSMA expression in the neovasculature in 85% of NSCLC cases, which was clearly correlated to the clinical stage: patients at stages I and II presented higher percentages of PSMA expression compared to patients at stage III. This evidence concerns the gene FOLH1 and small cell lung carcinoma.